March 2026 may be remembered as one of the most consequential months rare disease medicines has seen in recent years. Four FDA approvals landed in the span of three weeks — each representing a first of its kind: the first gene therapy for LAD-I, the first enzyme replacement to cross the blood–brain barrier, the first approved treatment for cerebral folate transport deficiency, and a new disease-modifying option for achondroplasia. The common thread? A field that is no longer just treating symptoms, but increasingly rewriting the biology underlying disease.
That ambition was echoed in the pipeline. Atamyo, Genethon and Beam Therapeutics both reported early clinical data suggesting their gene-based approaches are delivering measurable biological effect — not just proof of concept, but signals strong enough to support pivotal development.
Yet the month also offered a sharp reminder that mechanism alone is not enough. Genentech’s emugrobart failed in both SMA and FSHD despite a compelling scientific rationale — a result that will reverberate beyond a single program, raising questions about the limits of muscle-growth pathway targeting neuromuscular diseases.
1. Clinical news & patient access
Neuromuscular biotech delivered a sharp mix of progress and setbacks this month of March 2026, underscoring both the momentum and the limits of current approaches. On the upside, programs from Genethon and Atamyo Therapeutics stood out, with Genethon reporting durable two-year efficacy in Duchenne muscular dystrophy and Atamyo showing strong early muscle targeting and functional gains in LGMD-R5. At the same time, the downside of the ledger was equally clear, as Genentech failed to demonstrate meaningful clinical benefit with its myostatin program in SMA and FSHD, while PepGen posted mixed results, including a discontinued DMD candidate despite early signs of activity in myotonic dystrophy. The month reinforces a familiar theme in neuromuscular disease: real scientific progress, but still no easy wins.
Mar. 3, 2026 — Rocket Pharmaceuticals — FDA approval of Kresladi (marnetegragene autotemcel) for severe leukocyte adhesion deficiency-I (LAD-I)
Rocket Pharmaceuticals announced that the FDA granted accelerated approval to Kresladi, an autologous hematopoietic stem cell–based gene therapy for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I, a rare primary immunodeficiency disorder. The decision follows clinical evidence showing restored CD18 expression and reduced severe infections, and the approval also earned Rocket a Rare Pediatric Disease Priority Review Voucher.
Mar. 4, 2026 — FDA approval of Yuviwel (navepegritide) for paediatric dwarfism
The FDA approved Yuviwel (navepegritide) for children with achondroplasia, the most common form of dwarfism. The therapy is designed as an injectable novel peptide-based biologic that counteracts overactive FGFR3 signalling, offering a disease-modifying approach that goes beyond symptom management and could meaningfully impact skeletal development when administered early in life.
Mar. 9, 2026 — Atamyo Therapeutics reports positive early clinical data for ATA-200 gene therapy in LGMD-R5 (γ-sarcoglycanopathy)
Atamyo Therapeutics announced promising results from the first patients treated with its AAV-based gene therapy, ATA-200, in a clinical trial targeting LGMD-R5 (γ-sarcoglycanopathy). The program builds on foundational research from Genethon, whose preclinical work has helped advance sarcoglycan-targeting gene therapy approaches now progressing into the clinic through Atamyo. At a dose of 1.0E+14 vg/kg, biopsies at 6 months showed robust target engagement, with more than 90% of muscle fibers expressing SGCG protein (90.2% and 92.1% in the first two patients), indicating widespread gene delivery. These findings were supported by a sustained reduction in CPK at 9 months, alongside early clinical improvements in ambulatory patients, including gains across timed functional assessments. Together, the data provide encouraging evidence of both biological activity and functional benefit, supporting further clinical development of ATA-200 as a potential disease-modifying therapy.
Mar. 10, 2026 — FDA approval of Wellcovorin for Cerebral Folate Transport Deficiency
The FDA approved Wellcovorin (leucovorin calcium) as the first treatment for patients with cerebral folate transport deficiency, a rare genetic neurological condition characterized by low levels of folate in the central nervous system. As an active folate replacement therapy, it delivers a bioavailable form of folate that can bypass defective transport into the brain, helping restore central nervous system folate levels and address symptoms ranging from seizures to developmental delay.
Mar. 12, 2026 — Ultragenyx — DTX301 gene therapy shows positive Phase 3 results in OTC deficiency
Ultragenyx reported that its investigational AAV8-based gene therapy DTX301 met a key co-primary endpoint in a Phase 3 trial for ornithine transcarbamylase (OTC) deficiency, a rare urea cycle disorder, with patients experiencing an 18% reduction in 24-hour plasma ammonia levels compared with placebo at 36 weeks after a single treatment; treated patients maintained ammonia control even while reducing ammonia-scavenger medications and relaxing dietary protein restrictions, and the therapy showed an acceptable safety profile, with full assessment of the second primary endpoint expected in 2027.
Mar. 11, 2026 — Genethon — GNT0004 gene therapy confirms sustained efficacy in Duchenne muscular dystrophy
Genethon announced long-term efficacy data for its investigational gene therapy GNT0004 in Duchenne muscular dystrophy (DMD), reporting that boys treated at the therapeutic dose (3×10¹³ vg/kg) maintained clinical benefit two years after a single intravenous administration, including sustained gains in motor function compared with natural history controls, persistent reductions in muscle damage biomarkers such as creatine phosphokinase (CPK), and a favorable safety profile with no serious adverse events. These results support progression into the ongoing pivotal Phase 3 trial enrolling ambulatory patients and reinforce the potential of low-dose micro-dystrophin gene therapy to slow disease progression in DMD.
Mar. 19, 2026 — Genentech — Emugrobart fails to improve muscle outcomes in SMA and FSHD trials
Genentech reported that its investigational antibody emugrobart, designed to inhibit myostatin and promote muscle growth, did not demonstrate meaningful clinical benefit in two studies evaluating rare neuromuscular diseases. The therapy was assessed in the Phase 2/3 MANATEE trial in spinal muscular atrophy (SMA) and the Phase 2 MANOEUVRE trial in facioscapulohumeral muscular dystrophy (FSHD). Despite the mechanistic rationale of blocking myostatin to increase muscle mass, the results failed to translate into clinical improvement, highlighting the challenges of targeting muscle growth pathways in progressive neuromuscular disorders and potentially impacting broader development plans.
Mar. 25, 2026 — Denali Therapeutics — FDA approval of Avlayah (tividenofusp alfa-eknm) for Hunter syndrome (MPS II)
Denali Therapeutics announced that the FDA granted accelerated approval to Avlayah, an enzyme replacement therapy engineered to cross the blood–brain barrier, for the treatment of neurologic manifestations of Hunter syndrome, a rare X-linked lysosomal storage disorder. The approval was based on surrogate endpoint data showing reduction in cerebrospinal fluid heparan sulfate, considered reasonably likely to predict clinical benefit.
Beam Therapeutics reported updated Phase 1/2 data showing that its gene-editing therapy BEAM-302 raised and maintained alpha-1 antitrypsin (AAT) levels above the ~11 µM protective threshold, with mean levels around 16 µM, supporting advancement to pivotal development. Alpha-1 Antitrypsin Deficiency is a rare inherited disorder that causes low AAT levels, leading to lung damage (such as emphysema and COPD) and sometimes liver disease; current treatments include AAT augmentation therapy (protein infusions), bronchodilators, oxygen therapy, and in severe cases lung or liver transplantation, but none address the underlying genetic cause.
Mar. 25, 2026 — Maze Therapeutics — MZE829 shows positive Phase II results in APOL1 kidney disease, challenging Vertex in the field
Maze Therapeutics reported positive topline data from its Phase II HORIZON trial of the oral APOL1 inhibitor MZE829 in patients with APOL1-mediated kidney disease, showing a ~35.6% reduction in proteinuria (uACR) at 12 weeks and meaningful response rates across key patient subgroups, establishing clinical proof-of-concept and positioning the company in direct competition with Vertex Pharmaceuticals, which is also advancing APOL1-targeted therapies in this indication; the results strengthen Maze’s position in a competitive landscape of precision kidney disease treatments and support plans to move into later-stage development.
Mar. 31, 2026 — PepGen — Mixed results in Duchenne and myotonic dystrophy programs
PepGen reported disappointing results for its Duchenne muscular dystrophy (DMD) candidate PGN-EDO51, which failed to achieve sufficient dystrophin production in clinical testing, leading to the discontinuation of the program despite an acceptable safety profile. At the same time, its myotonic dystrophy type 1 (DM1) candidate PGN-EDODM1 showed early signs of efficacy, including meaningful improvements in RNA splicing correction, and continues to advance in clinical development, although regulatory feedback has introduced additional scrutiny. These outcomes highlight both the promise and the challenges of PepGen’s peptide-conjugated oligonucleotide platform in treating neuromuscular diseases, underscoring the difficulty of translating molecular activity into clinically meaningful benefits.
Patient access news
Europe
In Europe, Belgium has unveiled its Rare Diseases Plan (2026–2030), a comprehensive national strategy aimed at improving coordination of care, accelerating diagnosis, and enhancing access to orphan medicines through dedicated funding and structural reforms. This initiative reflects a broader European movement toward strengthening national rare disease frameworks in alignment with EU-level priorities. In parallel, regulatory progress continues at the European Medicines Agency, where the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for LOJUXTA® (lomitapide), an orphan therapy used in rare lipid disorders such as homozygous familial hypercholesterolemia, including in paediatric populations. This recommendation marks an important step toward expanding treatment options and underscores Europe’s continued efforts to improve access to advanced therapies for rare disease patients.
United States
A bipartisan push led by Representative Brett Guthrie is gaining momentum to improve access to rare disease therapies through proposed Medicaid reforms, with the goal of reducing coverage disparities and easing financial burdens for underserved patient populations. At the same time, policy debates are intensifying around drug pricing, as advocacy groups such as the Rare Access Action Project (RAAP) raise concerns over “Most Favored Nation” (MFN) pricing models. They argue that while intended to lower costs, such approaches could unintentionally discourage pharmaceutical investment in orphan drug development, potentially limiting long-term access to critical rare disease treatments. Together, these developments highlight the ongoing tension in the U.S. between expanding affordability and preserving innovation incentives in rare disease care.
2. Financings & Partnerships
Rare disease biotech continues to build momentum, fueled by advances in targeted gene therapy, growing adoption of AI in clinical and diagnostic workflows, and steady institutional investment in pipeline-stage companies. A multi-year $7.65 million collaboration between Cure Rare Disease and the LGMD2L Foundation is advancing a gene therapy for ANO5-related limb-girdle muscular dystrophy, while a partnership between NORD and OpenEvidence is integrating AI-driven tools into rare disease diagnosis and care. Meanwhile, investor confidence remains robust, with Mangrove Partners IM LLC increasing its stake in Rezolute, reflecting continued conviction in the long-term potential of rare disease-focused biopharma pipelines.
Mar. 2, 2026 — Cure Rare Disease and LGMD2L Foundation — Gene therapy development partnership for LGMD2L
Deal: Cure Rare Disease and the LGMD2L Foundation announced a multi-year, approximately $7.65 million partnership to advance a gene replacement therapy targeting ANO5-related limb-girdle muscular dystrophy (LGMD2L). The collaboration will support preclinical development and IND-enabling work, with the goal of advancing the program toward first-in-human studies.
Type: Development collaboration / partnership (ultra-rare neuromuscular disease gene therapy)
Mar. 12, 2026 — National Organization for Rare Disorders (NORD) and OpenEvidence — AI-driven rare disease knowledge partnership
Deal: The National Organization for Rare Disorders (NORD) partnered with OpenEvidence to deploy AI-powered tools aimed at improving rare disease diagnosis, education, and access to clinical information for both clinicians and patients worldwide. This initiative enhances digital infrastructure in rare disease care and supports earlier identification of rare conditions.
Type: Strategic partnership (digital health / AI for rare disease)
Mar. 17, 2026 — R1 Therapeutics exits stealth with $77.5M Series A to advance CKD treatment
Deal: R1 Therapeutics announced an oversubscribed $77.5 million Series A financing to support development of its first-in-class therapy AP306 for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis, securing backing from investors including Abingworth, F-Prime Capital and DaVita Venture Group; the company also obtained an exclusive global license to develop and commercialize AP306, a pan-phosphate transporter inhibitor expected to enter Phase 2b later this year, representing a novel approach to lowering serum phosphate with a reduced treatment burden compared with existing therapies.
Type: Series A financing (biotech / chronic kidney disease)
Deal: The AFM-Téléthon announced that the 2025 Téléthon raised €100,548,314 to support patient assistance and research into rare diseases, reaching its highest level since 2008. In particular, the funds will help advance innovative therapies, including gene therapy, in a field where the majority of conditions still lack effective treatments. The level of fund raised highlights a sustained public engagement and nationwide volunteer mobilization in a macroeconomic environment that has been tough for the past 5 years.
Type: Fundraising outcome (nonprofit / rare disease research)
Mar. 2026 — Mangrove Partners IM LLC — Increased investment in Rezolute, Inc.
Deal: Mangrove Partners IM LLC increased its equity position in Rezolute, Inc., a clinical-stage biopharmaceutical company with programs in rare disease. The investment represents roughly 2.3% of the fund’s portfolio, making Rezolute its 18th largest holding, reflecting continued institutional confidence in the company’s rare disease pipeline and development strategy.
Type: Equity investment (public biotech / rare disease-focused pipeline)
3. Research breakthroughs
New Hope for Rett Syndrome: A Promising Therapeutic Strategy
Rett syndrome (RTT), a rare neurological disorder caused by mutations in the MECP2 gene, currently has limited treatment options. While current treatments only mildly alleviate symptoms, new research presents a groundbreaking approach: modulating the alternative splicing of MECP2 to increase the production of the more efficiently translated MeCP2-E1 protein isoform. By deleting exon 2 in mouse models and patient-derived neurons, researchers achieved a 50–60% increase in MeCP2 levels, leading to significant improvements in neuronal morphology, function, and gene expression. Even in neurons with severe mutations, this strategy partially restored normal transcriptomic activity. The study also demonstrated the feasibility of using antisense oligonucleotides to promote isoform switching in vivo, paving the way for a potential new therapy for RTT patients with partially functional MECP2 alleles. This innovative approach offers renewed hope for more effective treatments in the future.
Breakthrough in Treating Congenital Dyserythropoietic Anemia Type II (CDAII)
A new study reveals a promising therapeutic strategy for Congenital Dyserythropoietic Anemia Type II (CDAII), a rare genetic blood disorder caused by mutations in the SEC23B gene. Researchers discovered that inhibiting lysine-specific demethylase 1 (LSD1)—a protein that suppresses the expression of SEC23A, a paralog of SEC23B—can effectively rescue the erythroid defects seen in CDAII. Using a small-molecule inhibitor (RN1), the team demonstrated that LSD1 inhibition boosts SEC23A expression in human erythroid cells without disrupting their growth or differentiation. Genetic and pharmacological approaches confirmed that LSD1 binds to and represses the SEC23A promoter, and its inhibition restores normal erythroid function in both human cell models and a CDAII mouse model. These findings suggest that LSD1 inhibitors could offer a novel, targeted therapy for CDAII patients, opening new avenues for treatment.
Upcoming events
📅 May 18–19, 2026 — 15th World Rare Diseases Congress 2026 — Prague, Czech Republic
Global forum covering research, policy, and clinical care for rare and orphan diseases, bringing together scientists, clinicians, advocates, industry, and regulators.
📅 June 3–4, 2026 — European Conference on Rare Diseases & Orphan Products (ECRD 2026) — Prague, CZ & Online
The flagship European policy and advocacy event for rare diseases, led by EURORDIS, addressing healthcare access, research, holistic care, and patient engagement.
📅 June 9–11, 2026 — World Orphan Drug Congress USA 2026 — Boston, MA, USA
One of the largest global gatherings dedicated to rare and orphan drug development, bringing together industry leaders, regulators, investors, and patient advocates.
📅 June 17–18, 2026 — 7th International Conference on Rare Diseases (RARE2026) — Kraków, Poland
Scientific conference covering gene therapy, omics, newborn screening, and translational research with global participation and expert speakers in the rare disease field.
📅 September 9–10, 2026 — Clinical Trials in Rare Diseases Conference 2026 — Princeton Marriott at Forrestal, Princeton, NJ, USA
Focused on innovative clinical trial design, patient recruitment, and regulatory strategies for rare disease therapeutics, connecting academia, biotech, and regulators.
📅 September 14–15, 2026 — 2nd European Congress on Rare Diseases and Orphan Drugs 2026 — London, United Kingdom
International forum featuring researchers, clinicians, policymakers, and pharmaceutical experts discussing new advances in diagnosis, orphan drug development, and health policy.
📅 October 22–23, 2026 — 4th International Conference on Rare Diseases and Orphan Drugs 2026 — Barcelona, Spain
Global scientific conference themed “From Discovery to Cure: Transforming Rare Disease Care,” highlighting cutting‑edge research, therapeutic innovation, and patient‑centered care models.
📅 October 25–27, 2026 — NORD Rare Diseases & Orphan Products Breakthrough Summit 2026 — Washington, DC, USA
Hosted by the National Organization for Rare Disorders (NORD), this premier U.S. summit unites patients, researchers, regulators, and biotech innovators to accelerate progress in rare disease treatments and policy.